MA44381A - Format d'anticorps hétérodimères multispécifiques - Google Patents

Format d'anticorps hétérodimères multispécifiques

Info

Publication number: MA44381A
Authority: MA; Morocco
Prior art keywords: antibody format; heterodimeric antibody; multispecific heterodimeric; multispecific; format
Prior art date: 2015-06-15

Application number

MA044381A

Other languages

English (en)

Inventor

Sebastian Meyer

David Urech

Original Assignee

Numab Innovation Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-06-15

Filing date

2016-06-15

Publication date

2019-01-23

2016-06-15 Application filed by Numab Innovation Ag filed Critical Numab Innovation Ag

2019-01-23 Publication of MA44381A publication Critical patent/MA44381A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA044381A 2015-06-15 2016-06-15 Format d'anticorps hétérodimères multispécifiques MA44381A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP15001758		2015-06-15

Publications (1)

Publication Number	Publication Date
MA44381A true MA44381A (fr)	2019-01-23

Family

ID=53434175

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA044381A MA44381A (fr)	2015-06-15	2016-06-15	Format d'anticorps hétérodimères multispécifiques

Country Status (13)

Country	Link
US (2)	US11236150B2 (fr)
EP (2)	EP3307776A1 (fr)
JP (3)	JP6839101B2 (fr)
KR (2)	KR20180012860A (fr)
CN (2)	CN107922486B (fr)
AU (3)	AU2016278586B2 (fr)
CA (1)	CA2989474C (fr)
EA (1)	EA201890041A1 (fr)
HK (1)	HK1245805A1 (fr)
IL (2)	IL293435B1 (fr)
MA (1)	MA44381A (fr)
MX (2)	MX395604B (fr)
WO (1)	WO2016202457A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA201890041A1 (ru) *	2015-06-15	2018-07-31	Нумаб Инновейшн Аг	Гетеродимерный полиспецифичный формат антител
EP3156417A1 (fr) *	2015-10-13	2017-04-19	Affimed GmbH	Anticorps fv multivalents
CA3065868C (fr) *	2017-06-05	2024-06-04	Numab Therapeutics AG	Nouveau format d'anticorps multispecifique heterodimerique
AU2018280681B2 (en)	2017-06-05	2025-01-23	Numab Therapeutics AG	Novel anti-CD3 antibodies
WO2018224439A1 (fr)	2017-06-05	2018-12-13	Numab Innovation Ag	Nouveaux anticorps anti-hsa
WO2018224441A1 (fr)	2017-06-05	2018-12-13	Numab Innovation Ag	Nouveaux anticorps anti-cd3
IL271127B2 (en)	2017-06-05	2024-10-01	Numab Therapeutics AG	Novel anti-hsa antibodies
EP3459968A1 (fr)	2017-09-20	2019-03-27	Numab Innovation AG	Nouvelles combinaisons de structure de domaines variables d'anticorps stables
SG11202002982YA (en)	2017-10-10	2020-04-29	Numab Therapeutics AG	Multispecific antibody
EP3470428A1 (fr)	2017-10-10	2019-04-17	Numab Innovation AG	Anticorps dirigés contre cd137 et leurs procédés d'utilisation
EP3470426A1 (fr)	2017-10-10	2019-04-17	Numab Therapeutics AG	Anticorps multi-spécifique
US11578133B2 (en)	2017-10-10	2023-02-14	Namab Therapeutics AG	Antibodies targeting CD137 and methods of use thereof
CA3074802A1 (fr)	2017-10-10	2019-04-18	Numab Therapeutics AG	Anticorps ciblant pdl1 et procedes d'utilisation associes
EP3470429A1 (fr)	2017-10-10	2019-04-17	Numab Innovation AG	Anticorps dirigés contre pdl1 et leurs procédés d'utilisation
EP3735254A4 (fr)	2018-01-05	2021-11-03	City of Hope	Liants de ligands multi-spécifiques
TWI839395B (zh)	2018-10-09	2024-04-21	瑞士商Ｎｕｍａｂ治療公司	靶向cd137的抗體及其使用方法
EP3636320A1 (fr)	2018-10-09	2020-04-15	Numab Therapeutics AG	Anticorps dirigés contre cd137 et leurs procédés d'utilisation
EP3689907A1 (fr)	2019-01-31	2020-08-05	Numab Therapeutics AG	Anticorps dirigés contre il-17a et leurs procédés d'utilisation
EP4591879A3 (fr)	2019-01-31	2025-10-22	Numab Therapeutics AG	Anticorps multispécifiques ayant une spécificité pour tnfa et il-17a, anticorps ciblant il-17a, et leurs procédés d'utilisation
EP3816185A1 (fr)	2019-11-04	2021-05-05	Numab Therapeutics AG	Anticorps multi-spécifique contra pd-l1 et antigène associé à une tumeur
EP3915580A1 (fr)	2020-05-29	2021-12-01	Numab Therapeutics AG	Anticorps multi-spécifique
CN115698088A (zh) *	2020-06-30	2023-02-03	和铂医药(上海)有限责任公司	免疫细胞衔接器多特异性结合蛋白及其制备和应用
TWI815136B (zh) *	2020-06-30	2023-09-11	大陸商和鉑醫藥（上海）有限責任公司	一種雙特異性抗體及其用途
EP3988568A1 (fr)	2020-10-21	2022-04-27	Numab Therapeutics AG	Traitement combiné
EP4019546A1 (fr)	2020-12-23	2022-06-29	Numab Therapeutics AG	Domaines variables d'anticorps qui se lient à il-31
WO2022136693A1 (fr)	2020-12-23	2022-06-30	Numab Therapeutics AG	Domaines variables d'anticorps et anticorps ayant une immunogénicité réduite
EP4019090A1 (fr)	2020-12-23	2022-06-29	Numab Therapeutics AG	Domaines variables d'anticorps liant il-4r
JP7846119B2 (ja)	2020-12-23	2026-04-14	ヌマブセラピューティクスアクチェンゲゼルシャフト	Ｉｌ－４ｒに結合する抗体可変ドメイン
US20240392003A1 (en) *	2021-02-02	2024-11-28	Numab Therapeutics AG	Multispecific antibodies having specificity for ror1 and cd3
CN115536749A (zh)	2021-06-29	2022-12-30	三生国健药业（上海）股份有限公司	三特异性抗体、其制备方法和用途
EP4183800A1 (fr)	2021-11-19	2023-05-24	Medizinische Hochschule Hannover	Nouveaux anticorps neutralisants du sars-cov-2
EP4273162A1 (fr)	2022-05-06	2023-11-08	Numab Therapeutics AG	Domaines variables d'anticorps et anticorps présentant une immunogénicité réduite
US20250382363A1 (en)	2022-05-06	2025-12-18	Numab Therapeutics AG	Antibody Variable Domains And Antibodies Having Decreased Immunogenicity
WO2024038095A1 (fr)	2022-08-16	2024-02-22	Iome Bio	Nouveaux anticorps anti-rgmb
WO2024240690A2 (fr)	2023-05-19	2024-11-28	Numab Therapeutics AG	Domaines variables d'anticorps et anticorps présentant une immunogénicité réduite

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002002781A1 (fr) *	2000-06-30	2002-01-10	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Proteines de fusion heterodimeres
ES2276735T3 (es)	2001-09-14	2007-07-01	Affimed Therapeutics Ag	Anticuerpos fv multimericos de cadena sencilla en tandem.
US20050003403A1 (en) *	2003-04-22	2005-01-06	Rossi Edmund A.	Polyvalent protein complex
WO2010132872A1 (fr)	2009-05-15	2010-11-18	Novimmune S.A	Polythérapies et méthodes utilisant des agents de modulation anti-cd3 et des antagonistes anti-tnf
LT2975051T (lt)	2009-06-26	2021-07-12	Regeneron Pharmaceuticals, Inc.	Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
GB201000467D0 (en)	2010-01-12	2010-02-24	Ucb Pharma Sa	Antibodies
WO2012088290A2 (fr) *	2010-12-22	2012-06-28	Abbott Laboratories	Protéines de liaison à trois domaines variables et leurs utilisations
TWI838039B (zh)	2011-03-28	2024-04-01	法商賽諾菲公司	具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2013003647A2 (fr)	2011-06-28	2013-01-03	Sea Lane Biotechnologies, Llc	Protéines de liaison à domaines variables empilés polyvalentes
US20150203591A1 (en) *	2012-08-02	2015-07-23	Regeneron Pharmaceuticals, Inc.	Mutivalent antigen-binding proteins
CA2900154A1 (fr)	2013-02-05	2014-08-14	Sanofi	Agent d'immuno-imagerie pour l'utilisation avec une therapie par un conjugue medicament-anticorps
EP2994487B1 (fr) *	2013-05-07	2019-10-09	F.Hoffmann-La Roche Ag	Molécules trimériques de liaison à l'antigène
US10077312B2 (en) *	2013-05-10	2018-09-18	Numab Therapeutics AG	CD3 and IL-23 receptor binding bispecific constructs and their use in the treatment of various diseases
CA2914829A1 (fr)	2013-06-26	2014-12-31	Numab Therapeutics AG	Structures d'anticorps
GB2518221A (en) *	2013-09-16	2015-03-18	Sergej Michailovic Kiprijanov	Tetravalent antigen-binding protein molecule
EP2930188A1 (fr)	2014-04-13	2015-10-14	Affimed Therapeutics AG	Molécule de liaison à l'antigène trifonctionnel
EA201890041A1 (ru) *	2015-06-15	2018-07-31	Нумаб Инновейшн Аг	Гетеродимерный полиспецифичный формат антител
EP3156417A1 (fr)	2015-10-13	2017-04-19	Affimed GmbH	Anticorps fv multivalents

2016
- 2016-06-15 EA EA201890041A patent/EA201890041A1/ru unknown
- 2016-06-15 WO PCT/EP2016/001002 patent/WO2016202457A1/fr not_active Ceased
- 2016-06-15 CN CN201680048188.4A patent/CN107922486B/zh active Active
- 2016-06-15 CA CA2989474A patent/CA2989474C/fr active Active
- 2016-06-15 CN CN202210532747.6A patent/CN115057936B/zh active Active
- 2016-06-15 US US15/736,747 patent/US11236150B2/en active Active
- 2016-06-15 KR KR1020187001156A patent/KR20180012860A/ko not_active Ceased
- 2016-06-15 EP EP16736380.3A patent/EP3307776A1/fr not_active Withdrawn
- 2016-06-15 IL IL293435A patent/IL293435B1/en unknown
- 2016-06-15 MX MX2017016188A patent/MX395604B/es unknown
- 2016-06-15 MA MA044381A patent/MA44381A/fr unknown
- 2016-06-15 AU AU2016278586A patent/AU2016278586B2/en active Active
- 2016-06-15 HK HK18105091.7A patent/HK1245805A1/zh unknown
- 2016-06-15 EP EP22160481.2A patent/EP4047020A1/fr active Pending
- 2016-06-15 JP JP2017564881A patent/JP6839101B2/ja active Active
- 2016-06-15 KR KR1020257019761A patent/KR20250091329A/ko active Pending
2017
- 2017-12-13 MX MX2022011472A patent/MX2022011472A/es unknown
- 2017-12-14 IL IL256314A patent/IL256314B/en unknown
2021
- 2021-02-12 JP JP2021021147A patent/JP7140861B2/ja active Active
2022
- 2022-01-29 US US17/588,262 patent/US11879005B2/en active Active
- 2022-08-18 AU AU2022218544A patent/AU2022218544B2/en active Active
- 2022-09-08 JP JP2022142827A patent/JP7457764B2/ja active Active
2025
- 2025-09-29 AU AU2025238141A patent/AU2025238141A1/en active Pending

Also Published As

Publication number	Publication date
WO2016202457A8 (fr)	2017-11-30
JP6839101B2 (ja)	2021-03-03
AU2016278586B2 (en)	2022-05-19
JP2018522545A (ja)	2018-08-16
CN107922486A (zh)	2018-04-17
EP4047020A1 (fr)	2022-08-24
EP3307776A1 (fr)	2018-04-18
MX395604B (es)	2025-03-25
CN115057936B (zh)	2025-05-30
KR20180012860A (ko)	2018-02-06
WO2016202457A1 (fr)	2016-12-22
IL256314B (en)	2022-06-01
CA2989474A1 (fr)	2016-12-22
CN115057936A (zh)	2022-09-16
JP2022177097A (ja)	2022-11-30
JP7457764B2 (ja)	2024-03-28
NZ738221A (en)	2024-10-25
AU2025238141A1 (en)	2025-10-23
US20220332797A1 (en)	2022-10-20
MX2022011472A (es)	2023-03-01
AU2022218544B2 (en)	2025-09-11
US11236150B2 (en)	2022-02-01
CN107922486B (zh)	2022-05-31
IL293435B1 (en)	2026-04-01
EA201890041A1 (ru)	2018-07-31
IL256314A (en)	2018-02-28
KR20250091329A (ko)	2025-06-20
HK1245805A1 (zh)	2018-08-31
AU2022218544A1 (en)	2022-09-15
US11879005B2 (en)	2024-01-23
MX2017016188A (es)	2018-07-06
US20180355024A1 (en)	2018-12-13
IL293435A (en)	2022-07-01
JP2021087436A (ja)	2021-06-10
JP7140861B2 (ja)	2022-09-21
CA2989474C (fr)	2023-09-05
AU2016278586A1 (en)	2018-01-04

Publication	Publication Date	Title
EP3359573A4 (fr)	2019-05-29	Marquage d'anticorps
EP3498840A4 (fr)	2020-05-06	Anticorps anti-lag-3
MA50352A (fr)	2020-08-19	Anticorps multispécifiques
EP3423089A4 (fr)	2019-10-23	Anticorps anti-tigit
EP3334757A4 (fr)	2019-04-03	Anticorps anti-tigit
EP3297671A4 (fr)	2019-02-06	Anticorps anti-ror1
MA49034A (fr)	2020-02-12	Anticorps anti-lag3
EP3589313A4 (fr)	2021-05-19	Anticorps anti-tigit
MA45004A (fr)	2019-03-27	Anticorps spécifiques anti-wt1-hla
MA47268A (fr)	2019-11-20	Anticorps anti-gpc3
EP3507307A4 (fr)	2020-04-22	Anticorps bispécifiques
EP3334763A4 (fr)	2019-04-03	Nouveaux anticorps anti-pd-1
MA44054A (fr)	2018-10-24	Plateforme d'anticorps bispécifique
MA47472A (fr)	2019-12-18	Anticorps
EP3684806A4 (fr)	2021-09-22	Nouveaux anticorps anti-cd3epsilon
MA44236A (fr)	2018-12-26	Anticorps anti-tgfbêta 2
EP3492591A4 (fr)	2020-04-01	Anticorps anti-b7-h4
EP3526247A4 (fr)	2021-04-14	Anticorps anti-il1-rap
EP2968553A4 (fr)	2016-10-19	Formulations d'anticorps
EP3399992A4 (fr)	2019-07-31	Anticorps autoréticulants
EP3484919A4 (fr)	2020-03-04	Anticorps anti-bêta-amyloïde
EP3617231A4 (fr)	2021-04-07	Anticorps anti-gpc-1
EP3349794A4 (fr)	2019-07-31	Anticorps anti-cd115
EP3596126A4 (fr)	2021-03-03	Nouveaux anticorps anti-trkb
MA51134A (fr)	2021-03-24	Anticorps anti-alpha-synucléine